The reports examined in this review varied in the type of VEGFR‐TKI used, dose, line of treatment, breakdown of prior therapy, and duration of treatment among cancer types, and they did not consider the impact of these differences on the occurrence of proteinuria. This evidence concerns the gene KDR and cancer.